Cancer Biomarker Assessment and Tumor Heterogeneity

Cancer Biomarker Assessment and Tumor Heterogeneity
Tumor Heterogeneity Scientists increasingly believe that the development of new and more efficient treatments will require a deeper understanding of (intra) tumoral heterogeneity. Pursuing this important goal, will require new and sophisticated too...
Read more

Rising to the Challenges of Tissue Based Research

Rising to the Challenges of Tissue Based Research
Nature of the Scientific Process George Bernard Shaw’s famous words, “Science never solves a problem without creating ten more” is stating an important fact about the the scientific process that, perhaps surprisingly, has profound implicat...
Read more

Aalborg University Hospital Selects Visiopharm for Cancer Diagnostics

Aalborg University Hospital Selects Visiopharm for Cancer Diagnostics
Visiopharm releases Oncotopix™ Diagnostics – a solution for computer assisted in-vitro diagnostics, including quantitative diagnostic immunohistochemistry (IHC) and In-Situ Hybridization (ISH). “Institute of pathology, Aalborg University Hospit...
Read more

A Platform for Tissue Based Biomarker Discovery

A Platform for Tissue Based Biomarker Discovery
Access to tissue based biomarkers has become key to cancer research, patient stratification in conjunction with clinical trials, and for companion diagnostics. In the context of cancer research and biomarker discovery, Tissue microarrays (TMAs) has c...
Read more

Automation and Increased Accuracy for Hormone Receptors in Breast Cancer

Automation and Increased Accuracy for Hormone Receptors in Breast Cancer
Join Visiopharm next week for a webinar titled, “Hormone Receptors in Breast Cancer: Automation and Increased Accuracy” on September 16, 2014 at 4 PM CET / 10 AM EST / 7 AM PST. Estrogen (ER) and progesterone (PR; PgR) evaluation is routinely use...
Read more

Visiopharm Fully Automated APP for Ki67 Assessment in Breast Cancer CE Marked for In-Vitro Diagnostic Use in Europe

Visiopharm Fully Automated APP for Ki67 Assessment in Breast Cancer CE Marked for In-Vitro Diagnostic Use in Europe
The Virtual Double Staining (VDS) Ki67 module for breast is a novel, patented and now CE-marked diagnostic APP intended for automated tumor/stroma separation and computation of the Ki67 labelling index for the identified tumor cells. The Visiopharm ...
Read more